TWI358290B - Topical nepafenac formulations - Google Patents
Topical nepafenac formulations Download PDFInfo
- Publication number
- TWI358290B TWI358290B TW094141182A TW94141182A TWI358290B TW I358290 B TWI358290 B TW I358290B TW 094141182 A TW094141182 A TW 094141182A TW 94141182 A TW94141182 A TW 94141182A TW I358290 B TWI358290 B TW I358290B
- Authority
- TW
- Taiwan
- Prior art keywords
- composition
- group
- patent application
- carbomer
- preservative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
第94141182號專利申諳案說明書暨申請專利範圍修正本修正曰期·· 100年丨丨月30曰 代表。、? 奈帕芬胺為一種已知化合物。可以數種已知方法製備 。請見’如’美國專利號5,475,034與4,313,949。本發明組 成物含有0.09-0.11%奈帕芬胺,較佳為〇1%奈帕芬胺。 除了奈帕芬胺之外,本發明之懸浮液組成物亦含有卡 波姆(carbomer) ’作為增稠劑或生理穩定性_增強劑。適用 於本發明之卡波姆(carbomer)亦已知為“羧基乙烯基聚合物 或缓基聚甲稀。為商業上可購得’如購自Noveon,Inc. (Cleveland,Ohi〇) ’ 此產品之商標名稱為 Carb〇p〇1®。Carb〇p〇1 聚合物為交聯性、含丙烯酸-聚合物。其係與丙烯基蔗糖或 烯丙基季戊四醇交聯。Carbopol聚合物為丙烯酸之聚合物, 經匸他川烷基丙烯酸酯修飾,並與烯丙基季戊四醇交聯。用 於本發明中之較佳卡波姆(carb〇mer)為與丙烯基蔗糖或烯 丙基季戊四醇交聯之丙烯酸聚合物,商品名稱為Carb〇p〇1® 974P。本發明組成物中卡波姆(carbomer)之濃度範圍通常為 0.4 — 0.6 %,較佳為〇 5 〇/〇。 本發明組成物亦含有眼科上可接受之非離子性界面活 性劑。許多眼科上可接受之非離子性界面活性劑為已知。 適用之非離子性界面活性劑包括,但不侷限於,泰洛沙伯 (tyloxapol);聚氧基乙烯基山梨醣酯,如聚山梨醣酯如聚 山梨醣酯60與聚山梨醣酯8〇 ;聚乙氧基化蓖麻油如 CremophorEL;聚乙氧基化氫化蓖麻油,如Hc〇 4〇以及 伯洛沙姆(P〇l〇xamers)。最佳之界面活性劑為泰洛沙伯 (tyloxapol)。若為泰洛沙伯(tyl〇xap〇1),該界面活性劑一般
Claims (1)
1358290 第94141182號專利申請案說明書暨申請專利範100年11月30曰 十、申請專利範圍:1^511 1. 一種可局部投藥之眼科用組成物,由下列組ik h a) 0.09-0.1i%(w/v)奈帕芬胺; b) 0_4 - 0.6% (w/v)卡波姆(carbomer); c) 一非離子性界面活性劑; d) —滲透強度-調整試劑,其量足以使該組成物具 250 - 350 mOsm/kg之渗透度; e) — pH-調整試劑,其量足以使該組成物具7.0-7.8 之pH值;以及 f) 水, 其中該組成物選擇性地包含一成份,選自於由防腐 劑與螯合劑組成之族群。 2. 如申請專利範圍第1項之組成物,其中該組成物含有 0.1% (w/v)奈帕芬胺。 3_如申請專利範圍第1項之組成物,其中該組成物含有 0.5% (w/v)卡波姆(carbomer)。 4. 如申請專利範圍第1項之組成物,其中該卡波姆 (carbomer)為一丙稀酸與稀丙基蔗糖或烯丙基季戊四醇 交聯之聚合物。 5. 如申請專利範圍第1項之組成物,其中該非離子性界面 活性劑為泰洛沙伯(tyloxapol)。 6. 如申請專利範圍第5項之組成物,其中該組成物包含 0.01% (w/v)泰洛沙伯’(tyloxapol)。 7. 如申請專利範圍第1項之組成物,其中該滲透強度-調整 13 1358290 第州侧2號專利申請案說明書暨申請專利範圍修正本修正 曰期:100年11月3〇 試劑係選自於由金屬氣化鹽與甘 8.如申請專利範圍第7項之組成物, 試劑包含氣化鈉與甘露醇。 曰 露醇組成之族群。 其中該滲透強度-調整 9.如申請專利範圍第8項之組成物,其中該組成物係包含 0‘3 - 0.5% (w/v)氯化鈉與2 _ 3% (w/v)甘露醇。 K)·如申請專職圍第9項之組成物,其中該组成物係包含 0.4% (w/ν)氯化鈉與2_4% (w/v)甘露醇。 11_如申請專利範圍第丨項之組成物,其#該pH調整試劑係 選自於由氫氣酸與氫氧化鈉組成之族群。 12·如申請專利·第丨項之組成物,其中肋成物之阳值 為 7·3 — 7·7。 13.如申請專利範圍第1項之組成物’其中該組成物含有防 腐劑與螫合劑二者。 14·如申請專利範圍第1項之組成物,其中該防腐劑係選自 於由鹵化苄二甲烴銨(benzaik〇nium halides);聚季銨鹽 -l(P〇lyquaternium-l);以及二氧化氯組成之族群。 15·如申請專利範圍第1項之組成物,其中該防腐劑為氣化 一 甲煙敍(benzalkonium chloride)。 16.如申請專利範圍第15項之組成物,其中該組成物包含 0.005%氣化苄二甲烴銨。 17.如申請專利範圍第1項之組成物,其令該螫合劑係選自 於由依地酸二鈉鹽;依地酸三鈉鹽;依地酸四鈉鹽;以 及二伸乙基胺五醋酸鹽(diethyleneamine pentaacetate)組 成之族群。 14 1358290 第94141182號專利申請案說明書暨申請專利範圍修正本修正日期:100年11月30曰 18. 如申請專利範圍第17項之組成物,其中該組成物包含 0.001 - 0.1% (w/v)依地酸二鈉鹽。 19. 如申請專利範圍第1項之組成物,用於治療一病患眼部 發炎病症。 20. —種可局部投藥之眼科用組成物,由下列組成 a) 0.1%(w/v)奈帕芬胺; b) 0.5% (w/v)卡波姆(carbomer); c) 0.01%(w/v)泰洛沙伯(tyloxapol); d) 0.4% (w/v)氣化鈉; e) 2.4%(w/v)甘露醇; f) 一pH-調整試劑,其量足以使該組成物具7.3 -7.7 之pH值; g) 0.0〇5% (w/v)氯化苄二曱烴銨; h) 0.01%依地酸二鈉;以及 i) 純水。 15
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63256204P | 2004-12-02 | 2004-12-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200626132A TW200626132A (en) | 2006-08-01 |
TWI358290B true TWI358290B (en) | 2012-02-21 |
Family
ID=35848959
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW094141182A TWI358290B (en) | 2004-12-02 | 2005-11-23 | Topical nepafenac formulations |
Country Status (24)
Country | Link |
---|---|
US (3) | US7834059B2 (zh) |
EP (1) | EP1819362B1 (zh) |
JP (2) | JP4968844B2 (zh) |
KR (1) | KR101289661B1 (zh) |
CN (1) | CN101068573A (zh) |
AR (1) | AR052252A1 (zh) |
AT (1) | ATE476200T1 (zh) |
AU (1) | AU2005311738B2 (zh) |
BR (1) | BRPI0518904B1 (zh) |
CA (1) | CA2586807C (zh) |
CY (1) | CY1110780T1 (zh) |
DE (1) | DE602005022756D1 (zh) |
DK (1) | DK1819362T3 (zh) |
ES (1) | ES2348249T3 (zh) |
HK (1) | HK1104225A1 (zh) |
MX (1) | MX2007006558A (zh) |
PL (1) | PL1819362T3 (zh) |
PT (1) | PT1819362E (zh) |
RU (1) | RU2007124638A (zh) |
SI (1) | SI1819362T1 (zh) |
TW (1) | TWI358290B (zh) |
UY (1) | UY29238A1 (zh) |
WO (1) | WO2006060618A2 (zh) |
ZA (1) | ZA200704763B (zh) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI358290B (en) | 2004-12-02 | 2012-02-21 | Alcon Inc | Topical nepafenac formulations |
US20060257487A1 (en) * | 2005-05-10 | 2006-11-16 | Alcon, Inc. | Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders |
EP1906916B1 (en) * | 2005-05-10 | 2008-10-29 | Alcon Inc. | Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders |
TW200812575A (en) * | 2006-04-28 | 2008-03-16 | Alcon Inc | Formulations containing amide derivatives of carboxylic acid NSAIDs for topical administration to the eye |
US20080057022A1 (en) * | 2006-08-30 | 2008-03-06 | Erning Xia | Ophthalmic Pharmaceutical Compositions and Uses Thereof |
CA2687717A1 (en) * | 2007-05-24 | 2008-12-18 | Aciex Therapeutics, Inc. | Formulations and methods for treating dry eye |
TWI531362B (zh) * | 2008-07-21 | 2016-05-01 | 艾爾康股份有限公司 | 具有治療劑遞送能力之眼科裝置 |
TW201023912A (en) | 2008-12-05 | 2010-07-01 | Alcon Res Ltd | Pharmaceutical suspension |
WO2010101971A1 (en) * | 2009-03-03 | 2010-09-10 | Alcon Research, Ltd. | Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye |
WO2010101989A1 (en) * | 2009-03-03 | 2010-09-10 | Alcon Research, Ltd. | PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
WO2011068872A2 (en) | 2009-12-03 | 2011-06-09 | Alcon Research, Ltd. | Carboxyvinyl polymer-containing nanoparticle suspension |
US9532222B2 (en) | 2010-03-03 | 2016-12-27 | Duo Security, Inc. | System and method of notifying mobile devices to complete transactions after additional agent verification |
US9544143B2 (en) | 2010-03-03 | 2017-01-10 | Duo Security, Inc. | System and method of notifying mobile devices to complete transactions |
US9467463B2 (en) | 2011-09-02 | 2016-10-11 | Duo Security, Inc. | System and method for assessing vulnerability of a mobile device |
AU2012351948A1 (en) * | 2011-12-16 | 2014-07-10 | Allergan, Inc. | Ophthalmic compositions comprising polyvinyl capralactam - polyvinyl acetate - polyethylene glycol graft copolymer |
EP3013790A1 (en) | 2013-06-27 | 2016-05-04 | Mylan Laboratories Ltd. | Process for the preparation of nepafenac |
CN104490861A (zh) * | 2014-11-21 | 2015-04-08 | 三明欣茂药业有限公司 | 一种缓释型奈帕芬胺眼用制剂 |
EP3470059B1 (en) | 2015-01-26 | 2020-04-01 | Bausch & Lomb Incorporated | Ophthalmic suspension composition |
US9930060B2 (en) | 2015-06-01 | 2018-03-27 | Duo Security, Inc. | Method for enforcing endpoint health standards |
CN107024550A (zh) * | 2016-12-21 | 2017-08-08 | 广州仁恒医药科技股份有限公司 | 奈帕芬胺眼用药物组合物的质控方法 |
CN106963730A (zh) * | 2016-12-22 | 2017-07-21 | 广州仁恒医药科技股份有限公司 | 高度稳定的奈帕芬胺眼用药物组合物 |
US10412113B2 (en) | 2017-12-08 | 2019-09-10 | Duo Security, Inc. | Systems and methods for intelligently configuring computer security |
US11658962B2 (en) | 2018-12-07 | 2023-05-23 | Cisco Technology, Inc. | Systems and methods of push-based verification of a transaction |
JP6994061B2 (ja) * | 2019-02-15 | 2022-01-14 | ノバルティス アーゲー | 4-(7-ヒドロキシ-2-イソプロピル-4-オキソ-4h-キナゾリン-3-イル)-ベンゾニトリルの製剤 |
CN114272207B (zh) * | 2022-01-21 | 2023-04-11 | 山东诺明康药物研究院有限公司 | 一种纳米晶混悬滴眼液及其制备方法 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1226344A (zh) | 1967-07-31 | 1971-03-24 | ||
SE400966B (sv) | 1975-08-13 | 1978-04-17 | Robins Co Inc A H | Forfarande for framstellning av 2-amino-3-(eller 5-)bensoyl-fenylettiksyror |
US4313949A (en) | 1979-09-26 | 1982-02-02 | A. H. Robins Company, Inc. | Method of producing an inhibitory effect on blood platelet aggregation |
US4254146A (en) | 1979-10-18 | 1981-03-03 | A. H. Robins Company, Inc. | 3-Benzoyl-2-nitrophenylacetic acids, metal salts, amides and esters |
IL61945A (en) | 1980-02-19 | 1984-09-30 | Robins Co Inc A H | 2-amino-3-(hydroxy(phenyl)methyl)phenylacetic acids,esters and amides and pharmaceutical compositions containing them |
US4503073A (en) | 1981-01-07 | 1985-03-05 | A. H. Robins Company, Incorporated | 2-Amino-3-(alkylthiobenzoyl)-phenylacetic acids |
IL64724A0 (en) | 1981-02-17 | 1982-03-31 | Robins Co Inc A H | 2-amino-3-(halobenzoyl)-methylphenylacetic acids and esters and salts thereof and pharmaceutical compositions containing them |
US4568695A (en) | 1983-12-07 | 1986-02-04 | A. H. Robins Company, Incorporated | 2-Amino-3-benzoyl-phenethylalcohols and intermediates therefor |
DE3668450D1 (de) | 1985-03-14 | 1990-03-01 | Smithkline Dauelsberg | 5-aminosalicylsaeurederivate von nicht-steroidalen entzuendungshemmenden sauren. |
US4851443A (en) | 1985-03-14 | 1989-07-25 | Smith Kline Dauelsberg, Gmbh | Carboxylic acid amides, compositions and medical use thereof |
US4683242A (en) | 1985-10-28 | 1987-07-28 | A. H. Robins Company, Incorporated | Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters |
DK406686D0 (da) | 1986-08-26 | 1986-08-26 | Hans Bundgaard | Carboxylsyrederivater |
US4910225A (en) | 1988-01-27 | 1990-03-20 | Senju Pharmaceutical Co., Ltd. | Locally administrable therapeutic composition for inflammatory disease |
US5461081A (en) | 1989-09-28 | 1995-10-24 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
US5521222A (en) | 1989-09-28 | 1996-05-28 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
US5624893A (en) | 1993-10-14 | 1997-04-29 | Alcon Laboratories, Inc. | Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation |
US5475034A (en) | 1994-06-06 | 1995-12-12 | Alcon Laboratories, Inc. | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders |
US6066671A (en) * | 1997-12-19 | 2000-05-23 | Alcon Laboratories, Inc. | Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides |
AR030346A1 (es) | 2000-08-14 | 2003-08-20 | Alcon Inc | Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico |
AR030345A1 (es) * | 2000-08-14 | 2003-08-20 | Alcon Inc | Metodo de tratamiento de desordenes relacionados con angiogenesis |
JP2005525408A (ja) | 2002-05-03 | 2005-08-25 | アルコン,インコーポレイテッド | アンフェナクまたはネパフェナクを用いる血管内皮増殖因子媒介性血管障害の処置方法 |
JP4500261B2 (ja) | 2003-01-21 | 2010-07-14 | 千寿製薬株式会社 | 2−アミノ−3−(4−ブロモベンゾイル)フェニル酢酸含有水性液剤 |
TWI358290B (en) | 2004-12-02 | 2012-02-21 | Alcon Inc | Topical nepafenac formulations |
-
2005
- 2005-11-23 TW TW094141182A patent/TWI358290B/zh active
- 2005-11-28 AR ARP050104964A patent/AR052252A1/es not_active Application Discontinuation
- 2005-11-29 UY UY29238A patent/UY29238A1/es not_active Application Discontinuation
- 2005-12-02 CN CNA200580041442XA patent/CN101068573A/zh active Pending
- 2005-12-02 EP EP05825662A patent/EP1819362B1/en active Active
- 2005-12-02 ZA ZA200704763A patent/ZA200704763B/xx unknown
- 2005-12-02 MX MX2007006558A patent/MX2007006558A/es active IP Right Grant
- 2005-12-02 RU RU2007124638/15A patent/RU2007124638A/ru unknown
- 2005-12-02 DK DK05825662.9T patent/DK1819362T3/da active
- 2005-12-02 BR BRPI0518904-7A patent/BRPI0518904B1/pt active IP Right Grant
- 2005-12-02 PL PL05825662T patent/PL1819362T3/pl unknown
- 2005-12-02 JP JP2007544521A patent/JP4968844B2/ja active Active
- 2005-12-02 SI SI200531107T patent/SI1819362T1/sl unknown
- 2005-12-02 AT AT05825662T patent/ATE476200T1/de active
- 2005-12-02 AU AU2005311738A patent/AU2005311738B2/en active Active
- 2005-12-02 KR KR1020077012413A patent/KR101289661B1/ko active IP Right Review Request
- 2005-12-02 DE DE602005022756T patent/DE602005022756D1/de active Active
- 2005-12-02 WO PCT/US2005/043545 patent/WO2006060618A2/en active Application Filing
- 2005-12-02 CA CA2586807A patent/CA2586807C/en active Active
- 2005-12-02 US US11/292,484 patent/US7834059B2/en active Active
- 2005-12-02 PT PT05825662T patent/PT1819362E/pt unknown
- 2005-12-02 ES ES05825662T patent/ES2348249T3/es active Active
-
2007
- 2007-09-25 HK HK07110438.2A patent/HK1104225A1/xx unknown
-
2010
- 2010-09-14 CY CY20101100830T patent/CY1110780T1/el unknown
- 2010-09-23 US US12/888,631 patent/US8071648B2/en active Active
-
2011
- 2011-10-05 US US13/253,648 patent/US8324281B2/en active Active
- 2011-11-25 JP JP2011257966A patent/JP2012041368A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI358290B (en) | Topical nepafenac formulations | |
ES2542728T3 (es) | Composiciones farmacéuticas que tienen la biodisponibilidad deseable | |
DE3872029T2 (de) | Rektal absorbierbare form von l-dopa. | |
US20090269369A1 (en) | Ophthalmic Composition Comprising Xanthan Gum and Glucose | |
RU2009149687A (ru) | Фармацевтические композиции и способы лечения сухих кератитов | |
JP3689123B2 (ja) | ビタミンa類可溶化水性点眼剤 | |
JP2011157388A (ja) | 点眼剤 | |
US20060257486A1 (en) | Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders | |
JP2009533462A (ja) | ブリモニジンおよびチモロールの組成物 | |
WO2007007894A1 (ja) | キサンタンガムおよびテルペノイドを含有する点眼剤 | |
JP2003206241A (ja) | 眼科用剤 | |
JP4687837B2 (ja) | 眼科用組成物 | |
JP4355574B2 (ja) | 点眼剤 | |
JP5132015B2 (ja) | 点眼剤組成物 | |
JP2007169232A (ja) | 眼科用組成物 | |
WO2013047373A1 (ja) | 亜塩素酸塩を含有する水性製剤 | |
JP5768720B2 (ja) | 点眼剤 | |
JP2001139493A (ja) | 人工涙液型点眼剤組成物 | |
WO2014192738A1 (ja) | 両性イオン性ソフトコンタクトレンズ用眼科用組成物 | |
JP2008110981A (ja) | 点眼剤 |